AstraZeneca is to invest 360 million USD in an advanced manufacturing facility in Ireland.
The investment will transform development and commercialization of new medicines, states the company.
“This is a tremendously proud moment for us all at AstraZeneca and I am delighted that we are bringing this very significant investment to Dublin which, with the support of the IDA, will create highly skilled jobs, nurture the country’s dynamic life sciences sector and allow for the development of high value-added medicines,” says Pascal Soriot, Chief Executive Officer, AstraZeneca.
AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the company’s global supply network is fit for future growth.
The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the company’s new medicines pipeline with speed and agility, it states.
Create about 100 highly skilled direct jobs
The planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The projectn was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.
“The future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.”
The investment programme is expected to significantly reduce commercialization lead times, costs and introduce more sustainable manufacturing processes, contributing to the company’s Ambition Zero Carbon programme. The future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.